ReviewNature reviews. Cancer2014
'Toxgnostics': an unmet need in cancer medicine.
Review in Nature reviews. Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Beyond the Basics: Exploring Pharmacokinetic Interactions and Safety in Tyrosine-Kinase Inhibitor Oral Therapy for Solid Tumors.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Prediction models of persistent taxane-induced peripheral neuropathy among breast cancer survivors using whole-exome sequencing.NPJ precision oncology · 2024Article
- The association of four genetic variants with myelosuppression in gemcitabine-treated Japanese is not evident in gemcitabine/carboplatin-treated Swedes.Basic & clinical pharmacology & toxicology · 2022Article
- Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model.Scientific reports · 2021Article
- "Pharmacogenetics of Cancer" -Cancer drug resistance (Alhambra, Calif.) · 2020Article
- Prognostic markers for colorectal cancer: estimating ploidy and stroma.Annals of oncology : official journal of the European Society for Medical Oncology · 2018Article
- Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies.Indian journal of surgical oncology · 2017Review
- Article
- Use of semantic workflows to enhance transparency and reproducibility in clinical omics.Genome medicine · 2015Article
- Clinical cancer research: the past, present and the future.Nature reviews. Clinical oncology · 2014Review
- Policy: EU data protection regulation--harming cancer research.Nature reviews. Clinical oncology · 2014Article
- Germline polymorphisms inNeuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
If we were to summarize the rationale that underpins medical oncology in a Latin aphorism, it might be 'veneno ergo sum'; that is, I poison, therefore I am. The burden of chemotherapy-associated toxicity is well recognized, but we have relatively few tools that increase the precision of anticancer drug prescribing. We propose a shift in emphasis from the focussed study of polymorphisms in drug metabolic pathways in small sets of patients to broader agnostic analyses to systematically correlate germline genetic variants with adverse events in large, well-defined cancer populations. Thus, we propose the new science of 'toxgnostics' (that is, the systematic, agnostic study of genetic predictors of toxicity from anticancer therapy).
Indexed as
Identifiers
24827503What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.